NVAX Q4 2017 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+92.9% YoY

Gross Profit

-$39M-376.9% margin

Operating Income

-$48M-458.9% margin

Net Income

-$51M-488.3% margin

EPS (Diluted)

$-3.22

QoQ Revenue Growth

+24.7%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$33M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$302M

Total Liabilities

$404M

Stockholders' Equity

-$102M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$5M	+92.9%
Gross Profit	-$39M	-$46M	+14.1%
Operating Income	-$48M	-$54M	+11.6%
Net Income	-$51M	-$57M	+11.0%